Shares of bioAffinity Technologies (NASDAQ: BIAF) experienced a dramatic surge on Tuesday, climbing 45.3% to $6.63 in early trading after the company announced a potential new application for its CyPath Lung test. The stock reached an intraday high of $8.60 before retreating, as trading volume exploded to 33.2 million shares within the first hour—a staggering 56 times the company's basic share count of 592,373 as of August 24.
CyPath Lung's New Proposed Use
The company suggested that CyPath Lung could be valuable for surveillance of patients who have undergone curative treatment for lung cancer. This would position the test as an additional monitoring tool alongside standard imaging when new nodules are detected. However, it is important to note that the test's published detection results have not been independently validated for this specific surveillance application.
Market Reaction and Volume
The market's response was immediate and intense. The opening surge saw BIAF shares trade as high as $8.60, representing a nearly 89% gain from the previous close of $4.56, before giving back some of those gains. The extraordinary volume, which was 56 times the basic share count, underscores the speculative nature of the move and the heightened interest in the company's prospects.
Commercial Potential
The potential market for surveillance is significant, particularly for a microcap company. As of early 2025, over 680,000 Americans had been previously diagnosed with lung cancer, and follow-up scans are typically recommended every six months during the first two years post-treatment. Chief Executive Maria Zannes highlighted that surveillance could lead to earlier intervention, describing it as a possible addition to early detection efforts. However, the company did not provide updated pricing, order forecasts, or revenue projections.
Financial Performance
bioAffinity's commercial activity has shown growth, though from a small base. In the second quarter of 2026, test volume increased 216% year-over-year, while first-half testing revenue rose 159%. The number of ordering offices and clinics grew 122%, and orders from existing clients were up 71%. Total second-quarter revenue increased 19% to $1.51 million, but direct costs of $1.09 million left only $423,000 before research and overhead expenses. Operating expenses reached $4.85 million, resulting in a net loss of $3.37 million.
CyPath generated approximately $835,000 in testing revenue during the first half of 2026, with 1,097 reports issued. While these figures indicate some adoption, the company remains far from break-even.
Balance Sheet and Financing
As of June 30, bioAffinity held $2.43 million in cash. In August, the company raised approximately $4 million in gross proceeds through pre-funded warrants, which was followed by a one-for-15 reverse stock split to meet Nasdaq listing requirements. The financing introduced additional shares and warrants that could significantly expand the share count if exercised.
Valuation and Risks
At the current share price of $6.63, bioAffinity's basic equity value is approximately $3.92 million, excluding potential warrant proceeds and future dilution. This illustrates how even modest increases in orders can lead to outsized moves in the share price.
The company's CyPath detection study demonstrated 92% sensitivity and a 99% negative predictive value, but those results were based on high-risk individuals with small lung nodules, not on surveillance after treatment. Investors should be aware that bioAffinity is still operating at a loss and may require additional funding. The surveillance application has yet to be proven, and warrant exercises could dilute existing shareholders. With low trading volume, the stock could experience sharp reversals.
Outlook
The next key test for bioAffinity is commercial validation—turning physician orders into sustainable revenue growth and controlling expenses. Tuesday's surge drew attention, but the company must demonstrate that CyPath can deliver consistent results in the surveillance setting before investors can fully embrace the story.
